Research Analysts Offer Predictions for MIRM Q3 Earnings

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) – Analysts at HC Wainwright lifted their Q3 2026 earnings estimates for shares of Mirum Pharmaceuticals in a research report issued on Monday, September 28th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of $0.07 per share for the quarter, up from their prior forecast of ($0.31). HC Wainwright has a “Buy” rating and a $195.00 price objective on the stock. The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($1.31) per share. HC Wainwright also issued estimates for Mirum Pharmaceuticals’ Q4 2026 earnings at ($0.11) EPS, Q3 2027 earnings at $0.35 EPS, FY2028 earnings at $5.38 EPS, FY2029 earnings at $7.21 EPS and FY2030 earnings at $10.03 EPS.

A number of other equities analysts also recently issued reports on the company. Morgan Stanley set a $144.00 price objective on Mirum Pharmaceuticals in a research report on Monday. Weiss Ratings upgraded shares of Mirum Pharmaceuticals from a “sell (d-)” rating to a “sell (d)” rating in a research report on Thursday, August 6th. Robert W. Baird upped their price objective on shares of Mirum Pharmaceuticals from $123.00 to $130.00 and gave the company an “outperform” rating in a research note on Tuesday. TD Cowen lowered their target price on shares of Mirum Pharmaceuticals from $145.00 to $140.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. Finally, Citigroup restated a “buy” rating and issued a $160.00 target price (up from $145.00) on shares of Mirum Pharmaceuticals in a report on Monday. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Mirum Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $142.56.

Mirum Pharmaceuticals Stock Down 0.5%

Shares of NASDAQ:MIRM opened at $87.54 on Wednesday. The firm has a market cap of $5.68 billion, a P/E ratio of -6.02 and a beta of 0.49. Mirum Pharmaceuticals has a 12-month low of $63.23 and a 12-month high of $130.00. The business has a fifty day simple moving average of $99.74 and a 200 day simple moving average of $101.45. The company has a quick ratio of 2.74, a current ratio of 2.86 and a debt-to-equity ratio of 1.28.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($1.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.32). Mirum Pharmaceuticals had a negative return on equity of 36.28% and a negative net margin of 139.18%.The business had revenue of $176.24 million for the quarter, compared to analyst estimates of $166.33 million. During the same quarter last year, the firm posted ($0.12) EPS. Mirum Pharmaceuticals’s revenue for the quarter was up 37.9% on a year-over-year basis.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Jupiter Topco LLC bought a new position in Mirum Pharmaceuticals in the second quarter worth approximately $691,672,000. Janus Henderson Group PLC increased its holdings in shares of Mirum Pharmaceuticals by 14.5% during the first quarter. Janus Henderson Group PLC now owns 6,945,813 shares of the company’s stock valued at $641,764,000 after acquiring an additional 880,505 shares in the last quarter. BlackRock Inc. bought a new stake in shares of Mirum Pharmaceuticals during the second quarter valued at approximately $513,945,000. ABS Investment Management LLC acquired a new position in shares of Mirum Pharmaceuticals during the second quarter worth approximately $245,847,000. Finally, William Blair Investment Management LLC bought a new position in shares of Mirum Pharmaceuticals in the 2nd quarter worth $164,453,000.

Insider Activity at Mirum Pharmaceuticals

In related news, CEO Christopher Peetz sold 30,000 shares of the business’s stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $98.68, for a total transaction of $2,960,400.00. Following the transaction, the chief executive officer owned 194,440 shares in the company, valued at $19,187,339.20. The trade was a 13.37% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Jolanda Howe sold 40,000 shares of the firm’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $100.00, for a total transaction of $4,000,000.00. Following the completion of the sale, the senior vice president owned 1,274 shares of the company’s stock, valued at $127,400. The trade was a 96.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 123,499 shares of company stock worth $12,854,484 in the last quarter. Company insiders own 8.32% of the company’s stock.

Key Stories Impacting Mirum Pharmaceuticals

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: The FDA approved Atebrioz for fibrodysplasia ossificans progressiva, an ultra-rare disorder involving abnormal bone formation. Approval expands Mirum’s commercial portfolio and follows PROGRESS study data showing reduced new heterotopic ossification lesion volume. Mirum wins FDA approval for Atebrioz
• Positive Sentiment: Mirum’s experimental hepatitis delta virus treatment brelovitug met the primary endpoint in the Phase III AZURE-1 study. The drug produced strong virologic response and alanine aminotransferase normalization results, supporting a potential future expansion into a serious liver-infection market. Mirum’s Brelovitug Meets Goal in Phase III AZURE-1 Study in HDV
• Positive Sentiment: Analysts raised their outlook for Mirum. HC Wainwright maintained a Buy rating and increased its price target to $195 from $140, while lifting its FY2027 EPS estimate to $1.42 from $1.28. Baird also raised its target to $130 and reiterated Outperform. Mirum Pharmaceuticals Stock Price Expected to Rise, HC Wainwright Analyst Says
• Neutral Sentiment: A head-to-head survey compared Mirum with Sarepta Therapeutics, but the report does not represent a new operating or clinical catalyst for MIRM. Mirum Pharmaceuticals and Sarepta Therapeutics Head-To-Head Survey

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, with an emphasis on liver and gastrointestinal disorders. The company’s medicines are intended to address serious conditions for which available treatment options are limited.

Mirum’s lead product is LIVMARLI (maralixibat), an oral bile acid transport inhibitor approved in the United States for the treatment of cholestatic pruritus associated with Alagille syndrome and progressive familial intrahepatic cholestasis in eligible patients.